ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-101.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -90.30% |
| Return on Assets (Trailing 12 Months) | -67.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.07 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 138.28M |
| Free Float | 121.13M |
| Market Capitalization | $273.79M |
| Average Volume (Last 20 Days) | 1.13M |
| Beta (Past 60 Months) | 0.39 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |